Skip to main content

Table 1 Description of study cohort and assessment of potential risk factors for CDI

From: Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections

  

CDI cases

Non-RT027

RT027

p valuesa

Median age

 

73.08 (range 54–87)

71.63

74.13

 

Sex

female

16

6

10

0.41

male

10

5

5

0.41

Hospitalization on septic/non-septic ward

septic ward

21

7d

14

0.04

all other wards

5

4 b,c

1

 

Primary diagnosis

periprosthetic infection

19

8

11

0.81

soft tissue / wound infection

4

1

3

 

spondylitis

2

2

0

 

osteomyelitis

1

0

1

 

Co-morbidities

renal insufficiency

12

4

8

0.41

diabetes

11

5

6

 

pneumonia

1

0

1

 

neoplasm

2

1

1

 

hepatic disease

2

1

1

 

Antimicrobial therapy

aminopenicillins

4

1

3

0.72

ureidopenicillins

6

2

4

0.42

fluoroquinolones

9

3

6

0.27

cephalosporins

13

5

8

0.24

clindamycin

7

3

4

0.81

rifampicin

13

6

7

0.69

Gastric acid suppressors

proton pump inhibitors/H2 blockers

25

11

14

 

Severity factors

creatinine (>1.5x103g/L)

7

3

4

0.99

leukocytosis (>1.5x109/L)

10

4

6

0.93

Antimicrobial CDI treatment

First episode

metronidazole po.

18

8

10

 

vancomycin po.

1

0

1

 

metronidazole iv. vancomycin po.

2

unknown

unknown

 

fidaxomicin po.

4

1

3

 

colectomy

1

0

1

 

no treatment

1

0

1

 

Recurrence

vancomycin po.

5

2

3

 

metronidazole iv. + vancomycin po.

1

0

1

 

fidaxomicin po.

3

1

2

 

fecal biota transplantation

1

0

1

 

Clinical outcome

cure

15

9

6

0.21

recurrence

10

3

7

0.37

death within 6 months

4

0

4

0.13

death CDI attributed

1

0

1

 

death CDI contributed

3

0

3

 
  1. a p values were determined with Fisher’s exact Test
  2. b Sequence type ST 6
  3. c Sequence types ST3, 14, 15
  4. d Sequence types ST3, 6, 8, 14, 92, and two unknown strains